Clinical Trials

2,031 enrolled 19 charts 1 FDA

BreastGastrointestinalGynecologicThoracic

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

71 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

279 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04281576 2024-11-14

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Phase NA Completed

28 enrolled

Stomach Neoplasms

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2 Terminated

29 enrolled

Stomach Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

30 enrolled

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT04861987 2024-10-10

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

Phase 1 Completed

23 enrolled

Phase 3 Active not recruiting

Neoplasms, Stomach Neoplasms

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

626 enrolled

Stomach Neoplasms

NCT02746796 2024-05-03

Study of ONO-4538 in Gastric Cancer

Phase 2/3 Completed

680 enrolled

Stomach Neoplasms

NCT03006705 2024-05-03

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

800 enrolled

Stomach Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Phase 2 Unknown

150 enrolled

Stomach Neoplasms

NCT06177041 2024-02-28

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3 Recruiting

486 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

67 enrolled 12 charts

Stomach Neoplasms

NCT06155383 2023-12-14

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2 Recruiting

90 enrolled

Stomach Neoplasms

NCT02494583 2023-04-13

MK-3475-062

763 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03745170 2023-03-01

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

650 enrolled

BreastDermatologicGastrointestinalHead & NeckLymphoidSarcoma

Stomach Neoplasms

NCT03775525 2022-12-23

GEN602

Phase 1 Unknown

127 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Basal Cell, Colonic Neoplasms, Lymphoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

318 enrolled 24 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Phase 3 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT01702558 2021-01-22

TRAXHER2

Phase 2 Terminated

182 enrolled 44 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT01774786 2020-12-30

JACOB

780 enrolled 24 charts

Stomach Neoplasms

NCT01748773 2019-10-09

TOXAG

34 enrolled

Stomach Neoplasms

NCT03817411 2019-05-07

Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

Phase 2 Unknown

90 enrolled

Stomach Neoplasms

NCT00215644 2018-11-02

MATRIX EG

72 enrolled 7 charts

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT01461057 2018-08-09

JOSHUA

30 enrolled 9 charts